LMLaurent Mascarell

Laurent Mascarell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laurent Mascarell has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expanding grass pollen allergomes: benefits for the molecular profiling of products used for in vivo allergy diagnosis

    by Thierry Batard, Véronique Bordas-Le Floch, Sonia Luce, Guillaume Sarrailhé, Maxime Poncet, Karine Jain, Henri Chabre, Christel Dayang, Sophie Oztas, Benoît Vacherie, et al.

    Introduction: Grass pollens are major outdoor sources of aeroallergens worldwide. Compared with timothy ( Phleum pratense ), other common allergenic grasses have far fewer officially recognized pollen allergens, even though most, if not all, timothy allergens are expected to have homologous counterparts in related species. This study aimed to expand the pollen allergomes of sweet vernal-grass ( Anthoxanthum odoratum ), cocksfoot ( Dactylis glomerata ), rye-grass ( Lolium perenne ), and meadow-grass ( Poa pratensis ) to improve the molecular characterization of allergens products, particularly those used for in vivo allergy diagnosis. Methods: Grass pollen transcriptomes were sequenced. De novo assembly was followed by coding DNA sequence prediction, translation, and annotation. Each novel allergen homologous to one of the timothy pollen allergens Phl p 1–7 and 11–13 was cloned and expressed in E. coli . IgE reactivity of recombinant proteins was assessed by immunoblotting. Two-dimensional gel electrophoresis of pollen extracts was performed, and IgE-binding spots were identified by immunoblotting, excised, and analyzed by mass spectrometry using a database derived from the extended transcriptomes. Two-dimensional western blots were performed on grass pollen extracts and IgE-reactive spots were analyzed by mass spectrometry using the transcriptome-derived database. Mass spectrometry-based allergen characterization of products used for in vivo diagnosis of allergy by skin prick testing was performed using the extended allergomic database, in comparison with the official database. Results: Homologous counterparts of all timothy pollen allergens from groups 1–7 and 11–13 were found in all four other grass species studied. Varying degrees of sequence identity and similarity were observed, depending on the species and allergen group considered. Of the allergens that were successfully cloned and expressed, IgE reactivity was confirmed for nearly all recombinant protein. Additionally, novel allergens unrelated to the allergen groups studied were also identified. The enriched allergome information substantially enhanced the molecular resolution achieved in the characterization of diagnostic allergen products. Discussion: In-depth proteomics informed by transcriptomics enabled a major expansion of the pollen allergomes of the grass species studied. This extended allergomic knowledge, in turn, substantially improved the allergen characterization of in vivo diagnostic allergen products, confirming the added value of comprehensive grass pollen allergomes.

  • Pragmatic Strategies for Reducing Variability and Risk in Food Oral Immunotherapy

    by Thomas B. Casale, Cosby A. Stone, Martin D. Chapman, Stephen A. Tilles, Antonella Muraro, Anne-Marie Irani, Jaime Sánchez-López, Thierry Batard, Laurent Mascarell

    Oral immunotherapy (OIT) can be effective and relatively safe for the treatment of food allergies, especially when started early in life. Grocery store foods used in OIT protocols are often heterogeneous in allergen potency and display product-to-product, lot-to-lot, and unit-to-unit variations, due to raw material variability and processing. This variability complicates dosing and poses a potential risk of anaphylaxis and/or subtherapeutic efficacy for patients. To improve practice, a ‘gradient of standardization’ framework is proposed, comprising four product categories: products assumed to contain the allergens of interest, products known to contain the allergens but in unknown amounts, partially quantified products, and fully standardized preparations. Based on verified allergen content rather than protein amount, this classification would help clinicians weigh safety and efficacy against feasibility and move toward greater conformity and standardization, supporting evidence-based dosing and probably improving patient outcomes. Ideally, foods as medicines for OIT should be well-described, minimally processed, and, preferably, with defined allergen content. Precise dosing, consistent procedures, neutral vehicles, and validated allergen quantification tools could potentially ensure reproducibility, reduce risk, strengthen clinical effectiveness, and facilitate meaningful comparisons across clinical trials and research studies. We suggest that standardized “pharmaceutical grade” products, while not always a practical option, should be preferred when available.

  • Open Access

    Biphasic Effects on Allergen‐Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy

    by Lin Hsin, Simone Reinwald, Anouk von Borstel, Pei Mun Aui, Kirsten Deckert, P. Mark Hogarth, Laurent Mascarell, Mark Hew, Robyn E. O'HEhir, Menno C. van Zelm

    Background: Type 2 memory B cells (Bmem) are the reservoir of pathogenic IgE in allergies. Allergen immunotherapy (AIT) can change the course of disease, but if it involves reprogramming of allergen‐reactive Bmem remains unknown. Here, we examine how AIT affects allergen‐specific Bmem in house dust mite (HDM) allergic patients. Methods: HDM allergic patients were longitudinally evaluated over 18 months with or without sublingual HDM‐AIT. Visual analog scores, lung function tests, medication scores, serum IgE, and flowcytometric analysis of Der p 1 and Der p 2‐specific Type 2 Bmem were performed at t = 0, 4, 12, and 18 months. Results: Patients on HDM‐AIT showed clinical improvement over 18 months with reduced intake of other medications and increases in specific serum IgE, IgG2, and IgG4. Allergen‐specific Bmem and the proportions of Type 2 Bmem therein became more abundant at 4 and 12 months and showed upregulation of CD29 and IgG4. At 18 months, the Type 2 Bmem proportions were reduced. Conclusion: A biphasic Bmem response with early phenotypic changes followed by loss of the Type 2 state was observed during 18 months of AIT. As durable unresponsiveness takes 18 months of AIT, deletion of Type 2 Bmem is likely an important step in disease attenuation. Interventions that expedite this outcome may be beneficial in driving remission.


  • Open Access

    Climate-driven changes in pollen dynamics: increased loads and earlier, longer exposure

    by Jean-Pierre Besancenot, Laurent Mascarell

    There is unequivocal evidence that the climate is changing, and it is generally accepted that the trend will continue. Climate change is relevant to public health, as it can lead to alterations in the distribution and flowering phenology of plants and to changes in pollen exposure, with subsequent impacts on human health. The primary objective of this paper was to provide a quantitative synthesis of the available literature on the evolution of pollen season intensity and timing in plants with a higher allergenic potential. Six botanical families have been studied: Betulaceae (birch, hazel, alder), Cupressaceae, Oleaceae (olive, ash), Poaceae, Urticaceae, and Asteraceae (mugwort, ragweed). Three main indicators of the potential impact of climate change on pollination have been retained: the pollen integral, the start date of the pollen season, and the duration of the pollen season. The outcome is a dominant trend toward earlier and more abundant pollen seasons, particularly for trees that flower in winter and spring. In contrast, trends for grass or weeds that pollinate later are less consistent and often region-specific. The variations recorded are taxon-, site-, and period-dependent, with some species even showing opposing trends within the same botanical family, illustrating the complex interactions between biological adaptation and climatic variability. While the current influence of climate change on pollen production and phenology is well established, the magnitude of its future impact remains uncertain, and the diversity of methodologies and study durations limits the comparability of available data. Nevertheless, most projections support a continued, though possibly attenuated, increase in pollen intensity and season advancement. In any case, when combined with likely qualitative and quantitative changes in the concentration of allergens in pollen grains, the identified trends may already have, and will very likely continue to have, an impact on both allergic sensitizations, the prevalence of seasonal symptoms, and their severity, thus affecting their diagnosis, prevention, and treatment.


  • Comparison of an FDA-approved peanut oral immunotherapy product with peanut food products

    by Thomas B. Casale, Cosby A. Stone, Martin D. Chapman, Stephen A. Tilles, Anne-Marie Irani, Jaime Sánchez-López, Thierry Batard, Laurent Mascarell


  • Open Access

    Influence of the definition of the standardization unit on the in vitro potency of cat allergen extracts

    by Thierry Batard, Stéphane Dreux, Karine Jain, Delphine Baveux, Christelle Péguillat, Sylvie Villardsaussine, Henri Chabre, Mélanie Bilong, Christel Dayang, Laurent Mascarell

    In a previous study, we conducted an in vitro comparison of two sublingual allergy immunotherapy products, namely, house dust mite (HDM) Staloral 300 IR/mL produced by Stallergenes Greer, and HDM Osiris 300 IR/mL produced by ALK-Abelló. Although both products are labeled with the same unit, that is, the index of reactivity (IR), the definition of this unit is different depending on the product. This resulted in HDM Staloral 300 IR/mL displaying a higher total allergenic activity (TAA) and higher contents in major allergens and proteins. The aim of this study was to extend the comparison to cat sublingual extracts, that is, to cat Staloral 300 IR/mL from Stallergenes Greer and cat Osiris 300 IR/mL from ALK-Abelló. While both cat allergen extracts were qualitatively similar, in that they exhibited similar protein and allergen profiles, cat Staloral 300 IR/mL displayed a 2 times higher TAA than cat Osiris 300 IR/mL (according to an in-house method) and contained 1.6 time more proteins, 1.3 and 1.9 time more major allergens Fel d 1 and Fel d 4, respectively. No conclusions on clinical efficacy or safety can be drawn from these data.


  • Enhanced benefit from house dust mite immunotherapy in subjects with low serum levels of LILRA5 or CCL25

    by Véronique Bordas‐Le Floch, Anja Heider, Duygu Yazici, Sonia Luce, Cezmi A. Akdis, Laurent Mascarell


  • Open Access

    Allergen Immunotherapy for the Prevention and Treatment of Asthma

    by Thierry Batard, Camille Taillé, Laurent Guilleminault, Andrzej Bozek, Véronique Bordas‐Le Floch, Oliver Pfaar, Walter G. Canonica, Cezmi Akdis, Mohamed H. Shamji, Laurent Mascarell

    Allergic asthma is the predominant phenotype among asthmatics. Although conventional pharmacotherapy is a central component in the management of asthma, it does not enable control of asthma symptoms in all patients. In recent decades, some uncontrolled asthmatic patients, especially those with allergic asthma, have benefited from biological therapies. However, biologics do not address all the unmet needs left by conventional pharmacotherapy. Furthermore, it is noteworthy that neither conventional pharmacotherapy nor biological therapies have disease‐modifying properties. In this context, allergen immunotherapy (AIT) represents an indispensable component of the therapeutic arsenal against allergic asthma, due to its disease‐modifying immunological effects. In this review article, funded by an AIT manufacturer, we find clinical trials support AIT as the only treatment option able both to improve allergic asthma symptoms and to prevent the onset and worsening of the condition. For patients with severe asthma or other safety concerns, the combination of AIT and biologics offers very promising new treatment modalities for the management of allergic asthma.Trial Registration: clinicaltrials.gov identifier: NCT06027073


  • Open Access

    Impact of the standardization unit’s definition on the in vitro biological potency of allergen extracts

    by Thierry Batard, Stéphane Dreux, Matthieu Rouet, Karine Jain, Christelle Péguillat, Mathilde Delecroix, Sylvie Villardsaussine, Henri Chabre, Christel Dayang, Laurent Mascarell

    In Europe, allergen products from different manufacturers can be labeled using the same unit with yet different definitions of that unit, which may cause confusion, as is the case for the index of reactivity (IR). In this context, house dust mite (HDM) Staloral 300 IR/mL, from Stallergenes Greer, and HDM Osiris 300 IR/mL, from ALK-Abelló, were characterized in vitro. Qualitatively, namely in terms of protein and allergen profiles, the two products were similar. Quantitatively, and despite the same 300 IR/mL labeling, the two products were shown to have different biological potencies, with HDM Staloral 300 IR/mL displaying a 2.4 times higher total allergenic activity (TAA) than HDM Osiris 300 IR/mL. This higher biological potency of HDM Staloral 300 IR/mL was paralleled by higher allergen and protein contents, namely 1.5 times more Der p 1 and Der f 1, 3.0 times more group 2 allergens, 2.7 times more Der p 23, and 1.8 times more protein. In contrast, HDM Staloral 300 IR/mL was shown to contain far fewer culture medium-derived proteins than HDM Osiris 300 IR/mL.


  • Open Access

    Accurate determination of house dust mite sensitization in asthma and allergic rhinitis through cytometric detection of Der p 1 and Der p 2 binding on Basophils (CytoBas)

    by Lin Hsin, Nirupama Varese, Pei Mun Aui, Bruce D. Wines, Laurent Mascarell, Mark P. Hogarth, Mark Hew, Robyn E. O’hehir, Menno C. van Zelm

    Background: House dust mite (HDM) is the commonest allergen trigger globally for allergic rhinitis and atopic asthma. To expedite accurate confirmation of allergen sensitization, we designed fluorescent allergen tetramers to directly stain specific IgE on basophils to detect allergen sensitization using the flow cytometric CytoBas assay. Methods: Recombinant proteins of major HDM allergens (component), Der f 1, Der p 1 and Der p 2 were biotinylated and conjugated with fluorochrome streptavidins as tetramers. Blood samples from 64 HDM-allergic patients and 26 non-HDM-sensitized controls were incubated with allergen tetramers for evaluation of basophil binding (CytoBas) and activation (BAT) with flow cytometry. Results: The tetramers effectively bound and activated basophils from allergic patients but not non-sensitized controls. CytoBas with Der p 1 as a single allergen had comparable sensitivity and specificity (92% and 100%) to BAT (91% and 100%), similarly for CytoBas with a single Der p 2 (95% and 96%) to BAT (95% and 87%) in detecting allergen sensitization. A positive staining for Der p 1 and/or Der p 2 was 100% sensitive and 96% specific for HDM allergy. Conclusions: CytoBas has diagnostic accuracy for group 1 and group 2 HDM allergens that is comparable to a BAT assay, but with additional advantages of multiple allergen components in a single tube and no requirement for in vitro basophil activation. These findings endorse a single, multiplex CytoBas assay for accurate and component-resolved diagnosis of aeroallergen sensitization in patients with allergic asthma and/or rhinitis. CAPSULE SUMMARY: A single flow cytometry stain of basophils (CytoBas) with both Der p 1 and Der p 2 provides >95% specificity and sensitivity for detection of functional HDM allergen sensitization. Highlights: Fluorescent tetramers of recombinant Der f 1, Der p 1 and Der p 2 can be used to detect functional IgE sensitization to house dust mite (HDM) by flowcytometric detection on basophils (CytoBas). A single CytoBas assay with inclusion of both Der p 1 and Der p 2 can detect HDM sensitization with >95% sensitivity and specificity.